The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27789138 |
355 |
Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors. |
Abbvie Bioresearch Center |
27171036 |
164 |
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
University of Nebraska Medical Center |
27078757 |
121 |
Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). |
Astrazeneca |
26851505 |
65 |
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
Palack£ |
26342867 |
52 |
Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. |
Sichuan University |
26349627 |
133 |
Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9. |
The University of Melbourne |
26115571 |
38 |
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. |
Eli Lilly |
25835317 |
63 |
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. |
Sichuan University |
25771484 |
5 |
Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold. |
Zhejiang University |
23933045 |
20 |
Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors. |
Nanjing University |
23352510 |
37 |
Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead. |
Roche Palo Alto |
23142618 |
66 |
Discovery of a novel series of 4-quinolone JNK inhibitors. |
Roche Palo Alto |
22726925 |
216 |
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. |
Cellzome |
23063403 |
21 |
Recent results in protein kinase inhibition for tropical diseases. |
Montclair State University |
21413800 |
56 |
A one-pot synthesis and biological activity of ageladine A and analogues. |
Macquarie University |
22365762 |
64 |
Pyridyl aminothiazoles as potent Chk1 inhibitors: optimization of cellular activity. |
Merck Research Laboratories |
18469809 |
41 |
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. |
Nerviano Medical Sciences Oncology |
20138512 |
82 |
Discovery of potent and bioavailable GSK-3beta inhibitors. |
Roche Palo Alto |
18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
18077425 |
197 |
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. |
Harvard Medical School |
18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University of Oxford |
17935989 |
146 |
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics. |
Abbott Laboratories |
21982796 |
108 |
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. |
The Institute of Cancer Research |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). |
Ambit Biosciences |
20462263 |
127 |
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. |
Cyclacel |
20397705 |
208 |
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. |
Nerviano Medical Sciences |
18842409 |
28 |
A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. |
Sunesis Pharmaceuticals |
18926699 |
30 |
Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. |
Sunesis Pharmaceuticals |
17395594 |
10 |
Cellular characterization of a novel focal adhesion kinase inhibitor. |
University of Virginia |
16682184 |
25 |
Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9. |
Banyu Tsukuba Research Institute |
16366598 |
51 |
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. |
Johnson & Johnson Pharmaceutical Research and Development |
30639897 |
48 |
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
The First Affiliated Hospital of Zhengzhou University |
32150405 |
75 |
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
Lebanese American University |
27491711 |
422 |
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties. |
Merck And |
31477350 |
80 |
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
Eli Lilly |
31514062 |
80 |
Recent advances in the development of cyclin-dependent kinase 7 inhibitors. |
Tianjin University of Science and Technology |
31381325 |
46 |
Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents. |
Chengdu University |
30978559 |
38 |
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. |
University of Padova |
30543440 |
86 |
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
University of South Australia Cancer Research Institute |
31622099 |
44 |
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88 |
Astrazeneca |
30197029 |
27 |
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors. |
Jiangnan University |
24803299 |
10 |
Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation. |
Institute of Experimental Botany Ascr and Palacky University |
18829454 |
12 |
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. |
University of Pittsburgh |
21035734 |
70 |
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. |
Cyclacel |